Navigation Links
Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
Date:6/23/2008

MOUNTAIN VIEW, Calif., June 23 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marriott Boston Copley Place in Boston, MA. The oral platform abstract presentation, "Inhaled Loxapine, a Dopamine Antagonist, Reduces Headache Pain in Patients Having an Acute Migraine Attack", is scheduled for Friday, June 27, 2008 at 10:55 a.m. Eastern Time, and will be presented in University Hall. AZ-104 is a lower dose version of AZ-004, which is in Phase 3 clinical development for the treatment of acute agitation in patients with schizophrenia or bipolar disorder.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed the enrollment of its first Phase 3 clinical trial. AZ-001 (Staccato prochlorperazine) for the acute tre
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
2. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
3. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
4. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
7. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
8. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
9. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
10. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
11. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 2015 Harwood Feffer LLP ( www.hfesq.com ) ... of Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company") (NASDAQ: ... its fiduciary duties to shareholders. On April ... results from its first Phase 3 registration trial of ... in the trial, Rhopressa failed to meet its primary ...
(Date:4/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/t2mvbz/endoscopy_global ... "Endoscopy Global Market - Forecast to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769) , , ,The global endoscopy market is ... growing at around 7.0% CAGR from 2014 to ... are aging population, increase in cancer, diabetes, and ...
(Date:4/27/2015)... April 27, 2015 Vermillion, Inc. ... gynecologic disease, announced today it will report ... market close on Monday, May 11, 2015, ... webcast at 4:30pm Eastern.Conference Call & Webcast: ... Pacific Domestic: , 888-556-4997International: , 719-457-2628Conference ID: ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3
... Va., Nov. 10, 2011 Primary healthcare distributors continue ... navigating economic, regulatory and business climate challenges in the ... in the U.S. Healthcare Industry released by the ... the non-profit research foundation of the Healthcare Distribution Management ...
... SKILLMAN, N.J., Nov. 10, 2011 ConvaTec Healthcare today announced that ... 15, 2011. David Johnson, CEO and George Kegler, CFO will host ... telephone. Questions and answers will follow. To participate ... 701-0354. To participate in the conference internationally, dial ...
Cached Medicine Technology:Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 2Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 3Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 4ConvaTec Healthcare Announces 2011 Third Quarter Earnings Call 2
(Date:4/27/2015)... Churchview Supportive Living, a Gardant affordable ... and Fashion Show from 10:30 a.m. to noon on ... 2626 W. 63rd St. in Chicago, serves low-income older ... to maintain their independence. , “Mothers, grandmothers, godmothers and ... Day Brunch,” said Director of Marketing Elizabeth Clippard. , ...
(Date:4/27/2015)... Church, VA (PRWEB) April 28, 2015 ... Works, **Presented by FDAnews and Ombu Enterprises**, June 16-17, ... If an FDA inspector came to a facility today, ... , If the answer is "maybe" or "no" ... Ombu Enterprises and FDAnews have a solution. , ...
(Date:4/27/2015)... 2015 How to Implement UDI:, Lessons ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/HowToImplementUDI ... of regulatory restraint, there’s plenty of time to get ... again. UDI deadlines are coming fast for all devicemakers ... Don’t delay, even if it seems there’s no rush. ...
(Date:4/27/2015)... April 28, 2015 Healthcare marketing ... paper called “Website Anatomy 101.” Available ... the necessary design elements for a successful hospital ... responsive design, user experience, search results and lead ... of a well-designed website on patient volume and ...
(Date:4/27/2015)... 2015 Women may have a more ... to a new study published online in the journal ... injury (MTBI), is a common medical problem affecting cognitive ... , In most cases, patients who experience MTBI will ... percent of MTBI patients will continue to experience persistent ...
Breaking Medicine News(10 mins):Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 2Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 3Health News:Smith & Jones Publishes 2015 Website Design White Paper 2Health News:Women Show Persistent Memory Impairment after Concussion 2Health News:Women Show Persistent Memory Impairment after Concussion 3
... 3 America,s oldest voluntary health organization is led ... Elected National Board Chair, after more than a decade ... successfully steered the American Lung Association to tackle key ... of his chairmanship has been to build on the ...
... variation in exposure, depending on several factors, , , TUESDAY, ... widely among people who undergo computed tomography (CT) scans, ... in the Feb. 4 issue of the Journal ... after the American Heart Association urged that CT scans ...
... for Southeastern Michigan Screens Patients DETROIT, Feb. 3 ... Saturday, February 7, over 300 children from the Detroit ... of the American Dental Association,s seventh annual "Give Kids ... their services that day to children who, because of ...
... Reinforce Commitment to Safety Net Partnerships and Quality ... Kaiser Permanente announced today that ... totaling approximately $43 million in the fourth quarter ... Community Benefit grants in the fourth quarter focused ...
... Feb. 3 Nearly three out ... insurance should cover the cost of addiction treatment ... their own health insurance would pay for substance ... Toward Addiction Survey" from Hazelden, the national nonprofit ...
... NASHVILLE, Tenn., Feb. 3 Healthcare Realty Trust,Incorporated (NYSE: ... cash dividend for the,quarter ended December 31, 2008. ... payable on March 5, 2009 to shareholders of record ... Realty Trust is a real estate investment trust that ...
Cached Medicine News:Health News:Maryland Lawyer Steve Nolan Advocates for Lung Health as National Board Chair of the American Lung Association 2Health News:Radiation From CT Scans Not Always the Same 2Health News:Radiation From CT Scans Not Always the Same 3Health News:Area Dentists, University of Detroit Mercy Team Up to Provide Free Dental Care to Low-Income, Uninsured Detroit-Area Children on Saturday, February 7 2Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 2Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 3Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 4Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 2Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 3Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: